Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma

Histopathology

Volumn 58, Issue 4, 2011, Pages 617-625

  Logullo, Angela Flavia ^a   Stiepcich, Mônica Maria Ágata ^b   de Toledo Osório, Cintia Aparecida Bueno ^b   Nonogaki, Sueli ^c   Pasini, Fátima Solange ^d   Rocha, Rafael Malagoli ^b   Soares, Fernando Augusto ^b   Brentani, Maria M ^d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ductal breast carcinoma; Fra 1; Prognosis; Progression

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR FRA 1;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; METASTASIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR AP-1; YOUNG ADULT;

EID: 79952734483     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03785.x     Document Type: Article

References (38)

1. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002; 2; 740-749.
2. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 2003; 3; 859-868.
3. Young MR, Colburn NH. Fra-1 a target for cancer prevention or intervention. Gene 2006; 379; 1-11.
4. Kustikova O, Kramerov D, Grigorian M et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol. Cell. Biol. 1998; 18; 7095-7105.
5. Philips A, Teyssier C, Galtier F et al. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol. Endocrinol. 1998; 12; 973-985.
6. Smith LM, Wise SC, Hendricks DT et al. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 1999; 18; 6063-6070.
7. Zajchowski DA, Bartholdi MF, Gong Y et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 2001; 61; 5168-5178.
8. Andersen H, Mahmood S, Tkach V et al. The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials. Oncogene 2002; 21; 4843-4848.
9. Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E, Berezin V. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. Oncogene 2003; 22; 5045-5054.
10. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005; 24; 1434-1444.
11. Andreolas C, Kalogeropoulou M, Voulgari A, Pintzas A. Fra-1 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in human colon carcinoma cells. Int. J. Cancer 2008; 122; 1745-1756.
12. Nakajima H, Mizuta N, Sakaguchi K et al. Aberrant expression of Fra-1 in estrogen receptor-negative breast cancers and suppression of their propagation in vivo by ascochlorin, an antibiotic that inhibits cellular activator protein-1 activity. J. Antibiot. (Tokyo) 2007; 60; 682-689.
13. Song Y, Song S, Zhang D et al. An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy. BMC Cancer 2006; 6; 298-304.
14. Chiappetta G, Ferraro A, Botti G et al. FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 2007; 7; 17-27.
15. Milde-Langosch K, Röder H, Andritzky B et al. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res. Treat. 2004; 86; 139-152.
16. Rakha EA, El-Sayed ME, Lee AH et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol. 2008; 26; 3153-3158.
17. The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Cancer 1997; 80; 798-1802.
18. Mangone FR, Brentani MM, Nonogaki S et al. Overexpression of Fos-related antigen-1 in head and neck squamous cell carcinoma. Int. J. Exp. Pathol. 2005; 86; 205-212.
19. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998; 11; 155-168.
20. Wolff AC, Hammond ME, Schwartz JN et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
21. Rakha EA, El-Sayed ME, Green AR, Paish EC, Lee AH, Ellis IO. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50; 434-438.
22. Lee S, Medina D, Tsimelzon A et al. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am. J. Pathol. 2007; 171; 252-262.
23. Hoque A, Sneige N, Sahin AA et al. Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol. Biomarkers Prev. 2002; 11; 587-590.
24. Roses RE, Paulson EC, Sharma A et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol. Biomarkers Prev. 2009; 18; 1386-1389.
25. Park K, Han S, Kim HJ, Kim J, Shin E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006; 48; 702-707.
26. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 2002; 15; 1318-1325.
27. Pommier SJ, Quan GG, Christante D et al. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann. Surg. Oncol. 2010; 17; 613-623.
28. Vial E, Sahai E, Marshall CJ. ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4; 67-79.
29. Song Y, Qian L, Song S et al. Fra-1 and Stat3 synergistically regulate activation of human MMP-9 gene. Mol. Immunol. 2008; 45; 137-143.
30. Casalino L, De Cesare D, Verde P. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent post-translational stabilization. Mol. Cell. Biol. 2003; 23; 4401-4415.
31. Chen H, Zhu G, Li Y et al. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res. 2009; 69; 9228-9235.
32. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol. Cell 2010; 38; 114-127.
33. Luo YP, Zhou H, Krueger J et al. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene 2010; 29; 662-673.
34. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur. J. Cancer 2005; 41; 2449-2461.
35. Malnou CE, Brockly F, Favard C, Moquet-Torcy G, Piechaczyk M, Jariel-Encontre I. Heterodimerization with different Jun proteins controls c-Fos intranuclear dynamics and distribution. J. Biol. Chem. 2010; 285; 6552-6562.
36. Hoeflich KP, O'Brien C, Boyd Z et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin. Cancer Res. 2009; 15; 4649-4664.
37. Hoadley KA, Weigman VJ, Fan C et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007; 8; 258-276.
38. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10; 515-527.